Evaluation of the E Test for the Assessment of Synergy of Antibiotic Combinations Against Multiresistant Pseudomonas Aeruginosa Isolates from Cystic Fibrosis Patients

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 2006 Jan 13

PMID 16402226

Citations 14

Authors

B Balke

M Hogardt

S Schmoldt

L Hoy

H Weissbrodt

S Haussler

Affiliations

Soon will be listed here.

Abstract

The determination of synergistic effects of antimicrobial drug combinations can lead to improved therapeutic options in the antibiotic treatment of cystic fibrosis patients who are chronically infected with multiresistant Pseudomonas aeruginosa isolates. The aim of this study was to evaluate the performance of the E test versus the standard agar dilution checkerboard susceptibility test in the assessment of synergy and, in addition, to determine the activity of two antimicrobial combinations against 163 multiresistant P. aeruginosa isolates from cystic fibrosis patients. The agreement between the checkerboard method and the E test was excellent (>90%) for nonmucoid as well as mucoid isolates from cystic fibrosis patients. The rate of synergy was higher for the antibiotic combination of ceftazidime and tobramycin (28.8% of the cystic fibrosis strains) than for the combination of meropenem and tobramycin (19.0%). However, the probability of synergy for the second antibiotic combination increased significantly when the synergy of the first antibiotic combination had already been demonstrated (Fischer's exact test, p=0.049). The results show that the E test is a valuable and practical method for routine microbiological diagnostics and can aid in the selection of improved antibiotic options in the treatment of cystic fibrosis patients chronically infected with P. aeruginosa.

Citing Articles

Diagnosis and Management of Cystic Fibrosis Exacerbations.

Milinic T, McElvaney O, Goss C Semin Respir Crit Care Med. 2023; 44(2):225-241.

PMID: 36746183 PMC: 10131792. DOI: 10.1055/s-0042-1760250.

The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis.

Saadh M, Lohrasbi A, Ghasemian E, Hashemian M, Etemad A, Dargahi Z Yale J Biol Med. 2022; 95(4):495-506.

PMID: 36568834 PMC: 9765336.

Antipseudomonal treatment decisions during CF exacerbation management.

VanDevanter D, West N, Sanders D, Skalland M, Goss C, Flume P J Cyst Fibros. 2022; 21(5):753-758.

PMID: 35466039 PMC: 9509480. DOI: 10.1016/j.jcf.2022.04.006.

Antimicrobial Synergy Testing: Comparing the Tobramycin and Ceftazidime Gradient Diffusion Methodology Used in Assessing Synergy in Cystic Fibrosis-Derived Multidrug-Resistant .

Okoliegbe I, Hijazi K, Cooper K, Ironside C, Gould I Antibiotics (Basel). 2021; 10(8).

PMID: 34439017 PMC: 8388873. DOI: 10.3390/antibiotics10080967.

Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis.

Lasko M, Huse H, Nicolau D, Kuti J Ann Clin Microbiol Antimicrob. 2021; 20(1):9.

PMID: 33468149 PMC: 7816365. DOI: 10.1186/s12941-021-00415-0.

References

Saiman L, Mehar F, Niu W, Neu H, Shaw K, Miller G . Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis. 1996; 23(3):532-7. DOI: 10.1093/clinids/23.3.532. View

Tummler B, Kiewitz C . Cystic fibrosis: an inherited susceptibility to bacterial respiratory infections. Mol Med Today. 1999; 5(8):351-8. DOI: 10.1016/s1357-4310(99)01506-3. View

Cappelletty D, Rybak M . Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1996; 40(3):677-83. PMC: 163179. DOI: 10.1128/AAC.40.3.677. View

Hancock R, Raffle V, Nicas T . Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1981; 19(5):777-85. PMC: 181521. DOI: 10.1128/AAC.19.5.777. View

Mouton J, den Hollander J, Horrevorts A . Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother. 1993; 31(6):919-26. DOI: 10.1093/jac/31.6.919. View

Regelmann W, Elliott G, Warwick W, Clawson C . Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis. 1990; 141(4 Pt 1):914-21. DOI: 10.1164/ajrccm/141.4_Pt_1.914. View

Smith A, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M . Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr. 1999; 134(4):413-21. DOI: 10.1016/s0022-3476(99)70197-6. View

HEINEMAN H, Lofton W . Unpredictable response of Pseudomonas aeruginosa to synergistic antibiotic combinations in vitro. Antimicrob Agents Chemother. 1978; 13(5):827-31. PMC: 352338. DOI: 10.1128/AAC.13.5.827. View

Meyer R, Liu S . In vitro synergy studies with ciprofloxacin and selected beta-lactam agents and aminoglycosides against multidrug-resistant Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 1988; 11(3):151-7. DOI: 10.1016/0732-8893(88)90017-x. View

10.

Weiss K, Lapointe J . Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1995; 39(11):2411-4. PMC: 162957. DOI: 10.1128/AAC.39.11.2411. View

11.

FitzSimmons S . The changing epidemiology of cystic fibrosis. J Pediatr. 1993; 122(1):1-9. DOI: 10.1016/s0022-3476(05)83478-x. View

12.

Miller M, Feinstein S, Chow R . Early effects of beta-lactams on aminoglycoside uptake, bactericidal rates, and turbidimetrically measured growth inhibition in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1987; 31(1):108-10. PMC: 174663. DOI: 10.1128/AAC.31.1.108. View

13.

Joyce L, DOWNES J, Stockman K, Andrew J . Comparison of five methods, including the PDM Epsilometer test (E test), for antimicrobial susceptibility testing of Pseudomonas aeruginosa. J Clin Microbiol. 1992; 30(10):2709-13. PMC: 270503. DOI: 10.1128/jcm.30.10.2709-2713.1992. View

14.

Gibson R, Burns J, Ramsey B . Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003; 168(8):918-51. DOI: 10.1164/rccm.200304-505SO. View

15.

Marley E, Mohla C, Campos J . Evaluation of E-Test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol. 1995; 33(12):3191-3. PMC: 228671. DOI: 10.1128/jcm.33.12.3191-3193.1995. View

16.

Manno G, Ugolotti E, Belli M, Fenu M, Romano L, Cruciani M . Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2003; 22(1):28-34. DOI: 10.1007/s10096-002-0852-8. View

17.

Chernish R, Aaron S . Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis. Curr Opin Pulm Med. 2003; 9(6):509-15. DOI: 10.1097/00063198-200311000-00011. View

18.

Chin N, Neu H . Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia. Diagn Microbiol Infect Dis. 1989; 12(4):343-9. DOI: 10.1016/0732-8893(89)90101-6. View

19.

White R, Burgess D, Manduru M, Bosso J . Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother. 1996; 40(8):1914-8. PMC: 163439. DOI: 10.1128/AAC.40.8.1914. View

20.

den Hollander J, Horrevorts A, van Goor M, Verbrugh H, Mouton J . Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1997; 41(1):95-100. PMC: 163667. DOI: 10.1128/AAC.41.1.95. View